Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ETST Earth Science Tech	$0.19 -8.3%	$0.19	$0.00 ▼ $0.25	$56.65M	1.95	105,724 shs	53,070 shs
SGMT Sagimet Biosciences	$7.09 -0.4%	$8.67	$1.73 ▼ $11.41	$230.40M	3.37	1.09 million shs	371,208 shs
TLSA Tiziana Life Sciences	$1.95 -5.4%	$1.81	$0.63 ▼ $2.60	$227.74M	-0.57	602,063 shs	252,392 shs
TRDA Entrada Therapeutics	$5.63 -8.3%	$6.38	$4.93 ▼ $21.79	$214.28M	-0.12	152,568 shs	101,258 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ETST Earth Science Tech	0.00%	+2.44%	+1.45%	+50.00%	+6.06%
SGMT Sagimet Biosciences	0.00%	-7.30%	-30.57%	+106.09%	+141.84%
TLSA Tiziana Life Sciences	0.00%	+4.57%	+10.75%	+30.38%	+68.85%
TRDA Entrada Therapeutics	0.00%	+16.51%	-6.12%	-18.13%	-62.83%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ETST Earth Science Tech	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SGMT Sagimet Biosciences	2.8295 of 5 stars	3.5	4.0	0.0	0.0	1.3	3.3	0.0
TLSA Tiziana Life Sciences	0.5407 of 5 stars	0.0	3.0	0.0	0.0	2.1	1.7	0.0
TRDA Entrada Therapeutics	2.9429 of 5 stars	3.5	3.0	0.0	0.0	2.3	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ETST Earth Science Tech	0.00	N/A	N/A	N/A
SGMT Sagimet Biosciences	3.00	Buy	$25.67	255.49% Upside
TLSA Tiziana Life Sciences	0.00	N/A	N/A	N/A
TRDA Entrada Therapeutics	3.00	Buy	$25.67	340.48% Upside

Current Analyst Ratings Breakdown

Latest ETST, TLSA, SGMT, and TRDA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2025	SGMT Sagimet Biosciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$28.00
8/8/2025	TRDA Entrada Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
8/7/2025	SGMT Sagimet Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$29.00
7/24/2025	SGMT Sagimet Biosciences	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$28.00
6/6/2025	SGMT Sagimet Biosciences	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$15.00 ➝ $27.00

(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ETST Earth Science Tech	$33.12M	1.78	$0.01 per share	18.15	$0.01 per share	20.00
SGMT Sagimet Biosciences	$2M	117.40	N/A	N/A	$5.08 per share	1.42
TLSA Tiziana Life Sciences	N/A	N/A	N/A	N/A	$0.04 per share	N/A
TRDA Entrada Therapeutics	$210.78M	1.05	$1.51 per share	3.87	$11.46 per share	0.51

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ETST Earth Science Tech	$3.25M	N/A	0.00	∞	N/A	7.93%	72.31%	41.28%	11/13/2025 (Estimated)
SGMT Sagimet Biosciences	-$45.57M	-$1.83	N/A	N/A	N/A	N/A	-39.88%	-38.40%	11/13/2025 (Estimated)
TLSA Tiziana Life Sciences	-$11.86M	N/A	0.00	∞	N/A	N/A	N/A	N/A	10/13/2025 (Estimated)
TRDA Entrada Therapeutics	$65.63M	-$1.78	N/A	N/A	N/A	-92.30%	-17.81%	-14.55%	11/4/2025 (Estimated)

Latest ETST, TLSA, SGMT, and TRDA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/13/2025	Q2 2025	SGMT Sagimet Biosciences	-$0.52	-$0.32	+$0.20	-$0.32	N/A	N/A
8/6/2025	Q2 2025	TRDA Entrada Therapeutics	-$0.86	-$1.04	-$0.18	-$1.04	$8.17 million	$1.98 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ETST Earth Science Tech	N/A	N/A	N/A	N/A	N/A
SGMT Sagimet Biosciences	N/A	N/A	N/A	N/A	N/A
TLSA Tiziana Life Sciences	N/A	N/A	N/A	N/A	N/A
TRDA Entrada Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ETST Earth Science Tech	0.01	0.91	0.67
SGMT Sagimet Biosciences	N/A	17.55	17.55
TLSA Tiziana Life Sciences	N/A	1.02	1.02
TRDA Entrada Therapeutics	N/A	18.64	18.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ETST Earth Science Tech	N/A
SGMT Sagimet Biosciences	87.86%
TLSA Tiziana Life Sciences	N/A
TRDA Entrada Therapeutics	86.39%

Insider Ownership

Company	Insider Ownership
ETST Earth Science Tech	24.90%
SGMT Sagimet Biosciences	14.70%
TLSA Tiziana Life Sciences	39.82%
TRDA Entrada Therapeutics	7.59%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ETST Earth Science Tech	3	294.30 million	221.02 million	Not Optionable
SGMT Sagimet Biosciences	8	32.52 million	27.74 million	Optionable
TLSA Tiziana Life Sciences	8	116.85 million	70.32 million	Optionable
TRDA Entrada Therapeutics	110	38.04 million	35.15 million	Optionable

ETST, TLSA, SGMT, and TRDA Headlines

Recent News About These Companies

Connor Clark & Lunn Investment Management Ltd. Sells 74,068 Shares of Entrada Therapeutics, Inc. $TRDA

August 23 at 4:15 AM | marketbeat.com

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Receives $25.67 Average Target Price from Analysts

August 18, 2025 | americanbankingnews.com

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Receives Average Rating of "Buy" from Brokerages

August 17, 2025 | marketbeat.com

Entrada (TRDA) Q2 Revenue Drops 98%

August 11, 2025 | theglobeandmail.com

HC Wainwright Issues Pessimistic Outlook for TRDA Earnings

August 11, 2025 | marketbeat.com

Roth Capital Issues Pessimistic Forecast for TRDA Earnings

August 11, 2025 | marketbeat.com

William Blair Issues Negative Forecast for TRDA Earnings

August 11, 2025 | marketbeat.com

Entrada Therapeutics (NASDAQ:TRDA) Downgraded to Sell Rating by Wall Street Zen

August 10, 2025 | marketbeat.com

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Analysts Are Cutting Their Estimates: Here's What You Need To Know

August 9, 2025 | finance.yahoo.com

Entrada Therapeutics (TRDA) to Release Quarterly Earnings on Tuesday

August 6, 2025 | marketbeat.com

Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Lags Revenue Estimates

August 6, 2025 | zacks.com

Entrada Therapeutics Reports Second Quarter 2025 Financial Results

August 6, 2025 | globenewswire.com

Entrada Therapeutics (TRDA) Soars 5.6%: Is Further Upside Left in the Stock?

July 31, 2025 | zacks.com

5am Ventures v sells Entrada Therapeutics (TRDA) stock for $202k

July 13, 2025 | investing.com

Entrada therapeutics (TRDA) director Parmar sells $202k in stock

July 13, 2025 | investing.com

Ventures V. L.P. 5Am Sells 6,935 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock

July 12, 2025 | insidertrades.com

Entrada Therapeutics (TRDA) 10% owners sell $866k in stock

July 3, 2025 | investing.com

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Major Shareholder Ventures V. L.P. 5Am Sells 6,422 Shares

July 2, 2025 | insidertrades.com

Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

June 3, 2025 | globenewswire.com

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 2, 2025 | globenewswire.com

Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients ...

May 29, 2025 | morningstar.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

ETST, TLSA, SGMT, and TRDA Company Descriptions

Earth Science Tech OTCMKTS:ETST

$0.19 -0.02 (-8.33%)

As of 02:08 PM Eastern

Earth Science Tech, Inc. focuses on health and wellness industry. It operates men's health telemedicine platform under brand Peak name; and operates pharmacy. The company offers supplements and topicals products. The company was formerly known as Ultimate Novelty Sports, Inc. and changed its name to Earth Science Tech, Inc. in March 2014. Earth Science Tech, Inc. was incorporated in 2010 and is headquartered in Miami, Florida.

Sagimet Biosciences NASDAQ:SGMT

$7.11 +0.00 (+0.00%)

As of 04:00 PM Eastern

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

Tiziana Life Sciences NASDAQ:TLSA

$1.95 -0.11 (-5.53%)

As of 04:00 PM Eastern

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.

Entrada Therapeutics NASDAQ:TRDA

$5.63 -0.51 (-8.26%)

Closing price 03:59 PM Eastern

Extended Trading

$5.63 0.00 (-0.05%)

As of 04:01 PM Eastern

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time